130 related articles for article (PubMed ID: 34842266)
1. Lenvatinib and Cu
Xu Q; Li Q; Yang Z; Huang P; Hu H; Mo Z; Qin Z; Xu Z; Chen T; Yang S
J Mater Chem B; 2021 Dec; 9(48):9908-9922. PubMed ID: 34842266
[TBL] [Abstract][Full Text] [Related]
2. A remotely controlled NIR-II photothermal-sensitive transgene system for hepatocellular carcinoma synergistic therapy.
Qiao S; Xin F; Wu M; Zheng Y; Zhao B; Zhang C; Liu X; Wei Z; Liu J
J Mater Chem B; 2021 Jun; 9(25):5083-5091. PubMed ID: 34124729
[TBL] [Abstract][Full Text] [Related]
3. Chiral Cu
Liu Y; Li H; Li S; Zhang X; Xiong J; Jiang F; Liu Y; Jiang P
ACS Appl Mater Interfaces; 2021 Dec; 13(51):60933-60944. PubMed ID: 34923825
[TBL] [Abstract][Full Text] [Related]
4. Targeted Therapy for Hepatocellular Carcinoma: Co-Delivery of Sorafenib and Curcumin Using Lactosylated pH-Responsive Nanoparticles.
Bian Y; Guo D
Drug Des Devel Ther; 2020; 14():647-659. PubMed ID: 32109990
[TBL] [Abstract][Full Text] [Related]
5. Evaluating the Effect of Lenvatinib on Sorafenib-Resistant Hepatocellular Carcinoma Cells.
Shi T; Iwama H; Fujita K; Kobara H; Nishiyama N; Fujihara S; Goda Y; Yoneyama H; Morishita A; Tani J; Yamada M; Nakahara M; Takuma K; Masaki T
Int J Mol Sci; 2021 Dec; 22(23):. PubMed ID: 34884875
[TBL] [Abstract][Full Text] [Related]
6. Oxygenic Enrichment in Hybrid Ruthenium Sulfide Nanoclusters for an Optimized Photothermal Effect.
Zhu H; Li Z; Ye E; Leong DT
ACS Appl Mater Interfaces; 2021 Dec; 13(50):60351-60361. PubMed ID: 34874695
[TBL] [Abstract][Full Text] [Related]
7. Boosting Chemodynamic Therapy
Yao J; Yang F; Zheng F; Yao C; Xing J; Xu X; Wu A
ACS Appl Mater Interfaces; 2021 Nov; 13(46):54770-54782. PubMed ID: 34780685
[TBL] [Abstract][Full Text] [Related]
8. Biodegradable Quantum Composites for Synergistic Photothermal Therapy and Copper-Enhanced Chemotherapy.
Tang HX; Liu CG; Zhang JT; Zheng X; Yang DY; Kankala RK; Wang SB; Chen AZ
ACS Appl Mater Interfaces; 2020 Oct; 12(42):47289-47298. PubMed ID: 32975929
[TBL] [Abstract][Full Text] [Related]
9. TPGS-Galactose-Modified Polydopamine Co-delivery Nanoparticles of Nitric Oxide Donor and Doxorubicin for Targeted Chemo-Photothermal Therapy against Drug-Resistant Hepatocellular Carcinoma.
Du Z; Mao Y; Zhang P; Hu J; Fu J; You Q; Yin J
ACS Appl Mater Interfaces; 2021 Aug; 13(30):35518-35532. PubMed ID: 34286569
[TBL] [Abstract][Full Text] [Related]
10. Antiproliferative Effect of Lenvatinib on Human Liver Cancer Cell Lines
Ogasawara S; Mihara Y; Kondo R; Kusano H; Akiba J; Yano H
Anticancer Res; 2019 Nov; 39(11):5973-5982. PubMed ID: 31704822
[TBL] [Abstract][Full Text] [Related]
11. Lenvatinib: a potential breakthrough in advanced hepatocellular carcinoma?
Oikonomopoulos G; Aravind P; Sarker D
Future Oncol; 2016 Feb; 12(4):465-76. PubMed ID: 26785762
[TBL] [Abstract][Full Text] [Related]
12. Plasmonic copper sulfide nanocrystals exhibiting near-infrared photothermal and photodynamic therapeutic effects.
Wang S; Riedinger A; Li H; Fu C; Liu H; Li L; Liu T; Tan L; Barthel MJ; Pugliese G; De Donato F; Scotto D'Abbusco M; Meng X; Manna L; Meng H; Pellegrino T
ACS Nano; 2015 Feb; 9(2):1788-800. PubMed ID: 25603353
[TBL] [Abstract][Full Text] [Related]
13. Platelet membrane-coated nanoparticles for targeted drug delivery and local chemo-photothermal therapy of orthotopic hepatocellular carcinoma.
Wu L; Xie W; Zan HM; Liu Z; Wang G; Wang Y; Liu W; Dong W
J Mater Chem B; 2020 Jun; 8(21):4648-4659. PubMed ID: 32373904
[TBL] [Abstract][Full Text] [Related]
14. Lenvatinib-zinc phthalocyanine conjugates as potential agents for enhancing synergistic therapy of multidrug-resistant cancer by glutathione depletion.
Wei G; Huang L; Jiang Y; Shen Y; Huang Z; Huang Y; Sun X; Zhao C
Eur J Med Chem; 2019 May; 169():53-64. PubMed ID: 30856406
[TBL] [Abstract][Full Text] [Related]
15. Hypoxia-mediated sorafenib resistance can be overcome by EF24 through Von Hippel-Lindau tumor suppressor-dependent HIF-1α inhibition in hepatocellular carcinoma.
Liang Y; Zheng T; Song R; Wang J; Yin D; Wang L; Liu H; Tian L; Fang X; Meng X; Jiang H; Liu J; Liu L
Hepatology; 2013 May; 57(5):1847-57. PubMed ID: 23299930
[TBL] [Abstract][Full Text] [Related]
16. Immunomodulatory activity of lenvatinib contributes to antitumor activity in the Hepa1-6 hepatocellular carcinoma model.
Kimura T; Kato Y; Ozawa Y; Kodama K; Ito J; Ichikawa K; Yamada K; Hori Y; Tabata K; Takase K; Matsui J; Funahashi Y; Nomoto K
Cancer Sci; 2018 Dec; 109(12):3993-4002. PubMed ID: 30447042
[TBL] [Abstract][Full Text] [Related]
17. STOML2 potentiates metastasis of hepatocellular carcinoma by promoting PINK1-mediated mitophagy and regulates sensitivity to lenvatinib.
Zheng Y; Huang C; Lu L; Yu K; Zhao J; Chen M; Liu L; Sun Q; Lin Z; Zheng J; Chen J; Zhang J
J Hematol Oncol; 2021 Jan; 14(1):16. PubMed ID: 33446239
[TBL] [Abstract][Full Text] [Related]
18. MT1JP-mediated miR-24-3p/BCL2L2 axis promotes Lenvatinib resistance in hepatocellular carcinoma cells by inhibiting apoptosis.
Yu T; Yu J; Lu L; Zhang Y; Zhou Y; Zhou Y; Huang F; Sun L; Guo Z; Hou G; Dong Z; Wang B
Cell Oncol (Dordr); 2021 Aug; 44(4):821-834. PubMed ID: 33974236
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of Polo-Like Kinase 1 by BI2536 Reverses the Multidrug Resistance of Human Hepatoma Cells In Vitro and In Vivo.
Li HY; Luo F; Li XY; Fu XF; He JF; Tian YZ; Zhu JJ; Chu XY; Zhao HL
Anticancer Agents Med Chem; 2019; 19(6):740-749. PubMed ID: 30836927
[TBL] [Abstract][Full Text] [Related]
20. Activation of the HGF/c-MET axis promotes lenvatinib resistance in hepatocellular carcinoma cells with high c-MET expression.
Fu R; Jiang S; Li J; Chen H; Zhang X
Med Oncol; 2020 Mar; 37(4):24. PubMed ID: 32166604
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
